Latest Breaking News On - Solid tumor cancers - Page 1 : comparemela.com

Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesAditi shastriJustine koenigsbergJared gollobEuropean hematology associationExchange commissionMontefiore medical centerAlbert einstein college of medicineKymera therapeutics incPresent new clinical dataOngoing phaseAnnual meetingChief medical officerClinical activityTargeted protein degraderRefractory hematologic

Johnson & Johnson Reports Q4 and Full-Year 2023 Results

2023 Fourth-Quarter reported sales growth of 7.3% to $21.4 Billion with operational growth of 7.2% and adjusted operational growth of 5.7% . Operational growth excluding COVID-19 Vaccine of.

Johnson medtechJoaquin duatoAshley mcevoyBiosense websterJohnson medtech acquires laminar incExchange commissionDevelopment expenseEuropean medicines agencyEuropean medicines agency seeking approval of lazertinibResearch development expenseConsumer health companyInterventional solutionsDrug administration grants full approvalCompany consumer healthChief executiveInnovative medicine

Johnson & Johnson : 2023 Third-Quarter Press Release & Supplemental Schedules -October 17, 2023 at 06:45 am EDT

Media contact: Investor contact: .

Joaquin duatoTesia williamsJessica mooreEuropean medicines agency seeking approvalExchange commissionDrug administration seekingEuropean academy of dermatologyFinalizes separation of kenvue incJohnson announces final results of exchangeJanssen highlights latest researchConsumer health companyTrueref technology for mappingNipocalimab clinical development program to address unmetConsumer healthInterventional solutionsJanssen to highlight latest research

Johnson & Johnson Reports Q3 2023 Results

2023 Third-Quarter reported sales growth of 6.8% to $21.4 Billion with operational growth of 6.4% and adjusted operational growth of 4.9% . Operational growth excluding COVID-19 Vaccine of.

Joaquin duatoJanssen to highlight latest researchFinalizes separation of kenvue incJohnson announces final results of exchangeConsumer healthEuropean commission approvesInterventional solutionsCompany consumer healthEuropean society of retina specialistsExchange commissionEuropean medicines agency seeking approval of erdafitinibEuropean academy of dermatologyJanssen highlights latest researchConsumer health companyDrug administration seeking full approvalEuropean medicines agency

MiNK Therapeutics Reports Second Quarter 2023 Results

- Randomized Phase 2 Trial in 2L Metastatic Gastric Cancer Planned to Launch at Memorial Sloan Kettering Cancer Center - iNKT Data Presented at AACR, ASGCT, and ATS Showed Benefit in Solid. -Today at 07:31 am- MarketScreener

United statesNew yorkJennifer buellYelena janjigianInternational conferenceMink therapeutics incAmerican thoracic societyCompany updatesAmerican association for cancer researchAmerican society of geneMetastatic gastric cancer plannedMemorial sloan kettering cancerData presentedSolid tumor cancersRespiratory distressEliminated tumors